Key result
Serum biomarkers offer potential utility in pediatric heart failure by aiding in clinical decision making, diagnosis, and prognosis.
Why the study?
Do serum biomarkers aid in clinical decision making, diagnosis, and prognosis in paediatric heart failure?
Do serum biomarkers aid in clinical decision making, diagnosis, and prognosis in paediatric heart failure?
Serum biomarkers offer a relatively low-cost, accessible tool that may aid in the diagnosis, prognosis, and clinical decision-making for pediatric heart failure.
Should not yet change pediatric HF practice; leaves open prospective validation of biomarker utility.
A biomarker is any measurable, surrogate characteristic, which reflects either the presence or the absence of a disease state. This can be a blood test, an imaging characteristic, an exercise parameter, and even a genetic profile. Serum biomarkers are particularly attractive in that their cost to the patient is relatively low in terms of money, time, risk, and ease of obtaining a sample. The potential benefits of a good biomarker are manifold. This manuscript will review serum biomarkers of proposed utility in paediatric heart failure, especially with respect to their ability to aid clinical decision making, diagnosis, and prognosis.
No takes yet. Share an insight, caveat, or question.
Kimberly Y. Lin (2015) conducted a review in Paediatric heart failure. Serum biomarkers was evaluated. Serum biomarkers offer potential utility in pediatric heart failure by aiding in clinical decision making, diagnosis, and prognosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: